Pacific Software Inc. Secures Strategic License Agreement with the University of California for Innovative Technology for Stimulating Collagen Production
Pacific Software has secured an exclusive licensing agreement with the University of California to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) for skincare and wound healing applications.
The technology, developed with over $6 million in research funding, will be spearheaded by Dr. Malcolm A. Leissring, who will become the Chief Science Officer of Pacific.
The IDE inhibitors, marketed as Dermatrix™, have shown significant capabilities in boosting collagen production, making them revolutionary for both wound healing and cosmetics. The agreement, effective as of March 5, 2024, also makes UC Regents an equity partner in Pacific.
- Pacific Software secures exclusive license, granting them unique market position.
- Over $6 million in research backing from esteemed institutions, enhancing credibility.
- IDE inhibitors shown to boost collagen production, promising for high-demand skincare market.
- Appointment of Dr. Malcolm A. Leissring as Chief Science Officer adds significant expertise.
- UC Regents become equity partners, indicating strong institutional support.
- Dermatrix™ confirmed to stimulate collagen production in peer-reviewed studies.
- Potential for Dermatrix™ to be a game-changer in both wound healing and cosmetics.
- No immediate revenue generation mentioned from the agreement.
- Potential high costs involved in further development and commercialization.
- Dependency on successful market acceptance of Dermatrix™.
- Risk associated with the effectiveness of the product in real-world applications.
DANA POINT, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Pacific Software Inc. ("Pacific"), a pioneer of groundbreaking skincare products, is thrilled to announce an exclusive licensing agreement with the Regents of the University of California ("UC Regents"). The agreement grants Pacific exclusive rights to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) with substantial importance for cosmetics and wound healing, which were developed at the University of California, Irvine (UCI). As part of the agreement, UC Regents will become an equity partner in Pacific.
IDE inhibitors represent a new branch of pharmacology pioneered by Dr. Malcolm A. Leissring, who will become Chief Science Officer of Pacific, developed through >
IDE inhibitors represent a revolutionary advance for both wound healing and cosmetics, because they maximize collagen production through an entirely novel mechanism, namely: by blocking the breakdown of insulin within skin. Though more widely known for its role in regulating blood sugar, insulin also directly stimulates collagen production within skin cells. Indeed, type 2 diabetes, which is characterized by a reduced ability to respond to insulin, frequently results in slow- or non-healing wounds, which in severe cases requires amputation, highlighting the importance of insulin for wound healing.
Insulin within skin is normally broken down by the enzyme IDE, which is abundant in wound fluid. IDE inhibitors block this enzyme, preventing insulin from being broken down, and thereby boosting insulin levels. The principal IDE inhibitor licensed by the company, which will be marketed as Dermatrix™, has been confirmed to stimulate collagen mRNA and protein production, as well as its secretion into the extracellular matrix by this mechanism in published, peer-reviewed laboratory experiments.
By virtue of its demonstrated ability to boost collagen production, Dermatrix™ has applications not only in wound healing, but also in cosmetics. Numerous cosmetic treatments, ranging from meso- and micro-needling, dermabrasion, laser therapy and numerous other procedures, actually work by creating wounds in a controlled manner, the healing of which requires collagen production. Topical application of Dermatrix™ in tandem with these procedures will maximize the level of collagen production stimulated by them, rendering Dermatrix™ a truly game-changing technology for the cosmetics sector.
This exclusive license, effective as of March 5, 2024, underscores Pacific's commitment to developing advanced skincare solutions and its dedication to bringing transformative products to market. The agreement not only aligns with Pacific’s mission to leverage cutting-edge research for societal benefit but also represents a significant step forward in the treatment and management of non-healing wounds typical of diabetes and related conditions.
Under the terms of the agreement, Pacific has the exclusive rights to utilize the patented peptide inhibitors, enabling the company to continue its commitment to developing the next wave of skincare innovations. This agreement signifies a crucial collaboration between academia and industry, aimed at fostering the development and commercialization of vital skincare innovations.
“We look forward to working closely with the UCI to navigate the path from research to real-world applications,” stated Stephen Israel, COO, “ensuring that the potential of our suite of products is fully realized for the benefit of customers and patients worldwide."
For more information about Pacific and our exciting new venture with the Regents of the University of California, please visit www.dreamaderm.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, PFSF's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various scientific and manufacturing programs, changes in future customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond PFSF's control. Except as may be required by law, Pacific Software, Inc. undertakes no obligation, and does not intend, to update these forward-looking statements after the date of this release.
About Pacific Software Inc.
Pacific Software Inc. is a Nevada-based technology firm that specializes in the development and commercialization of advanced skincare solutions. With a focus on innovation and quality, Pacific is dedicated to transforming cutting-edge research into practical applications that have a positive impact on society.
Contact Information:
Harrysen Mittler, CEO
Pacific Software Inc. 34145 Pacific Coast Hwy, Suite 196 Dana Point, CA 92629
Email: info@dreamaderm.com
Website: http://www.dreamaderm.com/
Phone: (310) 600-5064
FAQ
What is Pacific Software's recent licensing agreement about?
What are IDE inhibitors and their significance?
What is Dermatrix™?
Who will become the Chief Science Officer at Pacific Software?
When did the licensing agreement between Pacific Software and the UC Regents become effective?
What potential applications does Dermatrix™ have?
